Search Results for “artificial intelligence” – Page 9 – media

How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: Accurate Market Insights: AI as Your Detective Quickly Identify Customers and Markets Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. Monitor Competitors in Real-Time With ...
- Source: drugdu
- 424
- February 10, 2025
AI DeepSeek Drugdu Pharma Trade
Altman’s biotech company is raising $1 billion to extend human life by 10 years

San Francisco biotech company Retro Biosciences is raising $1 billion to support its mission to extend human life by 10 years through artificial intelligence (AI) technology. The company plans to advance its first drug to clinical trials this year. Retro Biosciences’ seed funding was provided by OpenAI CEO Sam Altman, with an amount of $180 million, and Altman will also invest additional funds in this round of Series A financing. The company is currently in talks with family offices, venture capital institutions, sovereign wealth funds, and a US “hyperscale” data center, which will provide it with the computing power needed to run AI models to accelerate drug development and testing. Retro Biosciences has developed a custom AI model in collaboration with OpenAI that can design proteins to temporarily convert ordinary cells into stem cells, thereby reversing the cellular aging process. The company plans to use the financing to fund clinical ...
- Source: drugdu
- 454
- February 1, 2025
Over 4.4 billion US dollars! GLP-1 opens a new chapter

There is no doubt that this is the era of GLP-1. Recently, in less than a month, three GLP-1 transactions were concluded one after another, involving an amount exceeding US$4.4 billion. First, Merck introduced the small molecule GLP-1RA HS-10535 from Hansoh Pharmaceuticals, and then Jixing Pharmaceutical introduced the global (except Greater China) development and commercialization rights of the oral small molecule GLP-1RA CX11 from Wingtech Pharmaceuticals. Recently, Verdiva Bio, an overseas Biotech company, has introduced the rights to once-weekly oral inoglutide from Xianweida Biotech. Among these transactions, a significant trend has attracted attention-the oral dosage form of GLP-1 drugs has become the focus of competition among pharmaceutical companies. Both emerging biotechnology companies and established pharmaceutical giants are all focusing their R&D resources on oral GLP-1 drugs, and a fierce competition around oral dosage forms has begun. The advantages are fully demonstrated . Currently, the mainstream GLP-1 drugs are mainly injections. ...
- Source: drugdu
- 321
- January 20, 2025
36 billion! Stryker swallows up the “peripheral” giant

On January 6, Stryker announced that it would acquire peripheral giant Inari Medical for $80 per share in cash, with a total transaction value of approximately $4.9 billion (approximately RMB 36 billion). The two companies expect to complete the transaction by the end of the first quarter of 2025, but it is subject to the tender of most of Inari’s outstanding shares, regulatory approval and other customary conditions. At the beginning of 2025, the merger and acquisition king Stryker “re-emerged” and threw in a large acquisition case. Behind the first acquisition of the year is the signal that Stryker has officially entered the peripheral vascular market. Why premium acquisitions are favored It is reported that Stryker’s acquisition was a premium acquisition. Before the transaction was announced, Inari Medical’s stock price was about $48, but the actual official acquisition announcement showed that Stryker acquired it at $80 per share in cash. ...
- Source: drugdu
- 174
- January 13, 2025
Two medical devices have entered the priority approval channel

According to the China Medical Device Innovation and Priority Approval Database, in December 2024, two medical devices entered the priority approval green channel in public announcements issued by local drug regulatory authorities across the country. They are: the disposable electronic endoscopic thoracoscopic laparoscopic catheter from Fujian Zhide Medical Technology Co., Ltd. (hereinafter referred to as Fujian Zhide), and the cognitive impairment assisted diagnosis and rehabilitation software from Hainan Boya Health Technology Co., Ltd. (hereinafter referred to as Hainan Boya). Fujian Zhide: Focusing on Endoscopy Fujian Zhide was established in April 2022 and is a company dedicated to the research and manufacturing of electronic endoscopic medical devices. The disposable 4K electronic endoscope technology developed by the research and design team of Fujian Zhide Optics has received widespread attention. This technology is both safe and convenient, not only greatly reducing the infection rate and improving cost-effectiveness, but also adapting to grassroots needs. ...
- Source: drugdu
- 176
- January 9, 2025
SAP’s massive layoffs

According to foreign media reports, the world’s third-largest software company is undergoing large-scale layoffs. German software giant SAP, the world’s third-largest software company, is cutting 9000 to 10000 positions instead of the original 8000 positions. Among them, in Germany, plans are underway to lay off approximately 3500 out of 25000 employees through early retirement and layoffs, accounting for 14%. Insiders revealed that initially around 5300 people expressed interest in the plan. However, SAP rejected many applications to prevent the loss of critical technologies. Among the nearly 3500 approved volunteer employees, about 80% retired early, about 2800 people, and 20% received severance pay plans. Public information shows that SAP was founded in 1972 and was once ranked as the world’s third largest software company by Forbes magazine. The company is dedicated to SAP, an enterprise management software business, and its potential market competitor is the American company Oracle. In the field ...
- Source: drugdu
- 342
- January 4, 2025
744 million! Medical Device Dark Horse completes C round of financing again

Recently, Precision Neuroscience (hereinafter referred to as Precision) announced that it has completed a new round of C round of financing of US$102 million (approximately RMB 744 million), bringing its total funds to US$155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Stanley F. Druckenmiller’s Duquesne Family Office and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research, and improve future versions of its artificial intelligence-driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones simply by thinking. On November 6 this year, Precision also completed a C round of financing, with a financing scale of US$93 million (approximately RMB 679 million). Founded in 2021, Precision is a company focused on developing brain-computer interface (BCI) technology. Its goal is to bring advanced brain-computer interface technology to ...
- Source: drugdu
- 307
- January 1, 2025
744 million! Medical equipment dark horse completes Series C financing again

According to the Medicine Intelligence Data Investment Pattern Database, Precision Neuroscience (hereinafter referred to as Precision) recently announced the completion of a new round of $102 million (contract 740 million RMB) Series C financing, bringing its total capital to $155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Duquesne Family Office of Stanley F. Druckenmiller, and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research work, and refine future versions of its AI driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones solely through thinking. In addition, according to the Medicine Intelligence Data Investment Pattern Database, Precision also completed a Series C financing on November 6th this year, with a financing scale of 93 million US dollars (contract 679 million RMB). Advanced Brain Computer Interface ...
- Source: drugdu
- 476
- December 28, 2024
Latest! “4 innovative medical devices” approved for marketing

Recently, the National Medical Products Administration approved the registration applications for four innovative products: “Intestinal Polyp Electronic Lower Gastrointestinal Endoscopy Image-Assisted Detection Software” by Changsha Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as Changsha Huiwei Intelligent), “Rotational Ablative Treatment Device” and “Disposable Coronary Ablative Catheter” by Shanghai Microport Melody Medical Technology Co., Ltd. (hereinafter referred to as Microport Melody), and “Disposable Magnetic Electric Positioning Pressure Monitoring Pulsed Electric Field Ablation Catheter” by Hunan Apt Medical Devices Co., Ltd. (hereinafter referred to as Apt Medical). Another product ofChangsha Huiwei Intelligent has been approved Changsha Huiwei Intelligence was established in 2020 and is a wholly-owned subsidiary of Suzhou Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as Huiwei Intelligence). Huiwei Intelligence was established in June 2019 and specializes in the research and development, production and sales of intelligent medical products. Driven by its independent core technologies in the fields ...
- Source: drugdu
- 159
- December 25, 2024
4 innovative medical devices approved for market launch

Recently, the National Medical Products Administration approved the registration applications for four innovative products: Changsha Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as “Changsha Huiwei Intelligent”)’s “Intestinal Polyp Electronic Lower Digestive Endoscopy Image Assisted Detection Software”, Shanghai Minimally Invasive Melody Medical Technology Co., Ltd. (hereinafter referred to as “Minimally Invasive Melody”)’s “Spinning Intervention Therapy Device” and “Disposable Coronary Spinning Grinding Catheter”, and Hunan Aptech Medical Equipment Co., Ltd. (hereinafter referred to as “Aptech Medical”)’s “Disposable Magnetoelectric Positioning Pressure Monitoring Pulse Electric Field Ablation Catheter”.  Changsha Huiwei Intelligence, another heavyweight product approved Changsha Huiwei Intelligent was established in 2020 and is a wholly-owned subsidiary of Suzhou Huiwei Intelligent Medical Technology Co., Ltd. (hereinafter referred to as “Huiwei Intelligent”). Huiwei Intelligent was established in June 2019, specializing in the research and development, production, and sales of intelligent medical products. Driven by independent core technologies in the fields of “artificial ...
- Source: drugdu
- 380
- December 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.